TKG Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

TKG Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-605	Closed	-$437K	–	104
2022 Q4	$437K	Buy	+605	New	+$446K	0.29%	59

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TKG Advisors's REGN Position: Q1 2023 in Review

TKG Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 605 shares — an estimated $437K sold.

TKG Advisors first reported a position in REGN in Q4 2022 and held it in 1 quarter. The position peaked at $437K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

TKG Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
TKG Advisors sold 605 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $437K.
TKG Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 1 quarter.
TKG Advisors's Regeneron Pharmaceuticals position peaked at $437K in Q4 2022.
1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on TKG Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.